Compare MOBX & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | GRDX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United Kingdom |
| Employees | 46 | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 28.6M |
| IPO Year | N/A | N/A |
| Metric | MOBX | GRDX |
|---|---|---|
| Price | $1.70 | $2.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 634.0K | 64.0K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.87 |
| 52 Week High | $4.25 | $6.93 |
| Indicator | MOBX | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 38.30 |
| Support Level | $0.19 | $2.58 |
| Resistance Level | $2.16 | $3.65 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 28.57 | 25.00 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.